Jacobs Levy Equity Management Inc. Makes New $870,000 Investment in Omnicell, Inc. $OMCL

Key Points

• Jacobs Levy Equity Management Inc. invested $870,000 in Omnicell, acquiring 24,884 shares, which represents approximately 0.05% of the company's stock as of their latest SEC filing.
• Wells Fargo & Company raised Omnicell's target price from $37 to $40, citing an "overweight" rating, while multiple other analysts have varying ratings reflecting a mixed market outlook.
• Omnicell reported earnings of $0.45 per share, exceeding estimates, with a year-over-year revenue growth of 5%, indicating positive financial momentum for the company.

Jacobs Levy Equity Management Inc. acquired a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 24,884 shares of the company's stock, valued at approximately $870,000. Jacobs Levy Equity Management Inc. owned 0.05% of Omnicell as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in OMCL. Point72 Hong Kong Ltd acquired a new stake in Omnicell in the 4th quarter worth about $101,000. AlphaQuest LLC raised its position in shares of Omnicell by 79.0% in the 1st quarter. AlphaQuest LLC now owns 6,400 shares of the company's stock valued at $224,000 after buying an additional 2,824 shares in the last quarter. Occudo Quantitative Strategies LP acquired a new position in shares of Omnicell in the 4th quarter valued at approximately $286,000. New Age Alpha Advisors LLC acquired a new position in shares of Omnicell in the 1st quarter valued at approximately $233,000. Finally, EntryPoint Capital LLC raised its position in shares of Omnicell by 21.6% in the 1st quarter. EntryPoint Capital LLC now owns 6,671 shares of the company's stock valued at $233,000 after buying an additional 1,184 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

OMCL has been the subject of a number of research analyst reports. Piper Sandler lowered their price objective on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Wells Fargo & Company upped their price objective on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Bank of America upped their price objective on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Finally, Wall Street Zen cut shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, Omnicell currently has an average rating of "Moderate Buy" and a consensus price target of $46.71.

Insider Transactions at Omnicell

In related news, EVP Corey J. Manley sold 3,880 shares of the stock in a transaction on Friday, September 12th. The shares were sold at an average price of $33.25, for a total transaction of $129,010.00. Following the transaction, the executive vice president directly owned 110,653 shares of the company's stock, valued at $3,679,212.25. This represents a 3.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.52% of the stock is currently owned by corporate insiders.

Omnicell Stock Down 3.5%

NASDAQ OMCL traded down $1.14 on Wednesday, hitting $31.18. 526,795 shares of the company were exchanged, compared to its average volume of 469,825. The company has a market cap of $1.43 billion, a PE ratio of 62.36, a PEG ratio of 7.06 and a beta of 0.82. Omnicell, Inc. has a 12 month low of $22.66 and a 12 month high of $55.74. The stock has a fifty day moving average of $30.86 and a 200-day moving average of $30.97. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell's revenue was up 5.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. As a group, analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.